Technical Analysis for CBIO - Catalyst Inc.
|Grade||Last Price||% Change||Price Change|
CBIO closed down 1.89 percent on Thursday, December 13, 2018, on 1.55 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical CBIO trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 13||50 DMA Resistance||Bearish||0.00%|
|Dec 13||Multiple of Ten Bearish||Other||0.00%|
|Dec 13||BB Squeeze Ended||Range Expansion||0.00%|
|Dec 13||Below Lower BB||Weakness||0.00%|
|Dec 13||Down 3 Days in a Row||Weakness||0.00%|
|Dec 13||Lower Bollinger Band Touch||Weakness||0.00%|
|Dec 13||Oversold Stochastic||Weakness||0.00%|
|Dec 12||50 DMA Resistance||Bearish||-1.89%|
|Dec 12||Bollinger Band Squeeze||Range Contraction||-1.89%|
|Dec 12||Stochastic Reached Oversold||Weakness||-1.89%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Catalyst Biosciences, Inc., a biopharmaceutical company, focuses on discovering and developing novel biopharmaceutical products based on engineered human proteases. The company designs its proteases to promote hemostasis and to prevent inflammation. Its pipeline of protease therapeutics include CB 813d/PF-05280602, an engineered Factor VIIa drug candidate that completed a Phase 1 clinical trial evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity. The company's pre-clinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of hemophilia B inhibitor patients; and an engineered Factor Xa for hemophilia and the control of bleeding in non-hemophilia patients. It also develops factor C3 for the prevention of renal delayed graft function and the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CBIO news...
|52 Week High||37.0|
|52 Week Low||8.6|
|200-Day Moving Average||16.3813|
|50-Day Moving Average||10.2314|
|20-Day Moving Average||10.491|
|10-Day Moving Average||10.32|
|Average True Range||0.5934|
|Chandelier Exit (Long, 3 ATRs )||9.5098|
|Chandelier Exit (Short, 3 ATRs )||11.5902|
|Upper Bollinger Band||11.1095|
|Lower Bollinger Band||9.8725|
|Percent B (%b)||0.0|
|MACD Signal Line||0.0305|
|Market Cap||42.53 Million|
|Num Shares||4.31 Million|
|Price-to-Earnings (P/E) Ratio||-0.70|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||10.62|
|Resistance 3 (R3)||10.68||10.50||10.50|
|Resistance 2 (R2)||10.50||10.31||10.47||10.45|
|Resistance 1 (R1)||10.18||10.19||10.09||10.12||10.41|
|Support 1 (S1)||9.68||9.81||9.59||9.62||9.33|
|Support 2 (S2)||9.50||9.69||9.47||9.29|
|Support 3 (S3)||9.18||9.50||9.25|
|Support 4 (S4)||9.12|